PYC Therapeutics Limited (ASX: PYC)

Market Cap	541.26M
Revenue (ttm)	22.06M
Net Income (ttm)	-37.73M
Shares Out	466.61M
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	193,870
Average Volume	494,362
Open	1.130
Previous Close	1.140
Day's Range	1.115 - 1.170
52-Week Range	1.080 - 2.000
Beta	0.66
RSI	30.61
Earnings Date	Feb 28, 2025

About PYC Therapeutics

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeuti...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 5
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: PYC

Financial Performance

In 2024, PYC Therapeutics's revenue was 22.06 million, an increase of 39.56% compared to the previous year's 15.81 million. Losses were -37.73 million, 65.5% more than in 2023.